Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Immobilization of Denosumab on Titanium Affects Osteoclastogenesis of Human Peripheral Blood Monocytes.

Beck F, Hartmann ES, Koehler MI, Redeker JI, Schluessel S, Schmitt B, Fottner A, Unger M, van Griensven M, Michael J, Summer B, Kunzelmann KH, Beutner R, Scharnweber D, Kostenuik PJ, Mayer-Wagner S.

Int J Mol Sci. 2019 Feb 26;20(5). pii: E1002. doi: 10.3390/ijms20051002.

2.

Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine.

Laufs U, Dent R, Kostenuik PJ, Toth PP, Catapano AL, Chapman MJ.

Eur Heart J. 2019 Sep 1;40(33):2825-2830. doi: 10.1093/eurheartj/ehy479. No abstract available.

PMID:
30169643
3.

Serum calcium concentration is maintained when bone resorption is suppressed by osteoprotegerin in young growing male rats.

Hohman EE, Hodges JK, Wastney ME, Lachcik PJ, Han CY, Dwyer D, Peacock M, Kostenuik PJ, Weaver CM.

Bone. 2018 Nov;116:162-170. doi: 10.1016/j.bone.2018.08.001. Epub 2018 Aug 2.

PMID:
30077758
4.

Selective inhibition of receptor activator of NF-κB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction.

Slavic S, Andrukhova O, Ford K, Handschuh S, Latic N, Reichart U, Sasgary S, Bergow C, Hofbauer LC, Kostenuik PJ, Erben RG.

J Mol Med (Berl). 2018 Jun;96(6):559-573. doi: 10.1007/s00109-018-1641-x. Epub 2018 May 8.

5.

Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss.

Liu M, Kurimoto P, Zhang J, Niu QT, Stolina M, Dechow PC, Feng JQ, Hesterman J, Silva MD, Ominsky MS, Richards WG, Ke H, Kostenuik PJ.

J Dent Res. 2018 Aug;97(9):1031-1038. doi: 10.1177/0022034518766874. Epub 2018 Apr 4.

PMID:
29617179
6.

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.

Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G.

Osteoporos Int. 2018 Mar;29(3):685-697. doi: 10.1007/s00198-017-4323-6. Epub 2017 Dec 19.

7.

Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells.

Streicher C, Heyny A, Andrukhova O, Haigl B, Slavic S, Schüler C, Kollmann K, Kantner I, Sexl V, Kleiter M, Hofbauer LC, Kostenuik PJ, Erben RG.

Sci Rep. 2017 Jul 25;7(1):6460. doi: 10.1038/s41598-017-06614-0.

8.

One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.

Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G.

Bone. 2017 Feb;95:143-150. doi: 10.1016/j.bone.2016.11.027. Epub 2016 Nov 25.

9.

Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus Monkeys.

Lee DC, Varela A, Kostenuik PJ, Ominsky MS, Keaveny TM.

J Bone Miner Res. 2016 Aug;31(8):1586-95. doi: 10.1002/jbmr.2830. Epub 2016 Apr 25.

10.

Influence of Fatigue Loading and Bone Turnover on Bone Strength and Pattern of Experimental Fractures of the Tibia in Mice.

Bonnet N, Gerbaix M, Ominsky M, Ammann P, Kostenuik PJ, Ferrari SL.

Calcif Tissue Int. 2016 Jul;99(1):99-109. doi: 10.1007/s00223-016-0124-8. Epub 2016 Mar 5.

PMID:
26945756
11.

Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect.

Bougioukli S, Jain A, Sugiyama O, Tinsley BA, Tang AH, Tan MH, Adams DJ, Kostenuik PJ, Lieberman JR.

Bone. 2016 Mar;84:93-103. doi: 10.1016/j.bone.2015.12.052. Epub 2015 Dec 23.

12.

Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice.

Lloyd SA, Morony SE, Ferguson VL, Simske SJ, Stodieck LS, Warmington KS, Livingston EW, Lacey DL, Kostenuik PJ, Bateman TA.

Bone. 2015 Dec;81:562-572. doi: 10.1016/j.bone.2015.08.021. Epub 2015 Aug 28.

PMID:
26318907
13.

Hypocalcaemia in patients with metastatic bone disease treated with denosumab.

Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ.

Eur J Cancer. 2015 Sep;51(13):1812-21. doi: 10.1016/j.ejca.2015.05.016. Epub 2015 Jun 17.

14.

Journal of Bone and Mineral Research: Volume 30, Issue 5, May 2015, Frontmatter page ii.

Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW.

J Bone Miner Res. 2015 Jul;30(7):1347. doi: 10.1002/jbmr.2543. Epub 2015 May 10. No abstract available.

15.

Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab.

Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW.

J Bone Miner Res. 2015 Jul;30(7):1280-9. doi: 10.1002/jbmr.2480. Erratum in: J Bone Miner Res. 2015 Jul;30(7):1347.

16.

Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.

Kostenuik PJ, Smith SY, Samadfam R, Jolette J, Zhou L, Ominsky MS.

J Bone Miner Res. 2015 Apr;30(4):657-69. doi: 10.1002/jbmr.2401.

17.

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.

Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ.

Endocrinology. 2014 Dec;155(12):4785-97. doi: 10.1210/en.2013-1905. Epub 2014 Sep 26.

PMID:
25259718
18.

Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.

Stolina M, Dwyer D, Niu QT, Villasenor KS, Kurimoto P, Grisanti M, Han CY, Liu M, Li X, Ominsky MS, Ke HZ, Kostenuik PJ.

Bone. 2014 Oct;67:305-13. doi: 10.1016/j.bone.2014.07.031. Epub 2014 Aug 2.

PMID:
25093263
19.

Matrix metalloproteinase-driven endochondral fracture union proceeds independently of osteoclast activity.

McDonald MM, Morse A, Mikulec K, Peacock L, Baldock PA, Kostenuik PJ, Little DG.

J Bone Miner Res. 2013 Jul;28(7):1550-60. doi: 10.1002/jbmr.1889.

20.

The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.

Goessl C, Katz L, Dougall WC, Kostenuik PJ, Zoog HB, Braun A, Dansey R, Wagman RB.

Ann N Y Acad Sci. 2012 Aug;1263:29-40. doi: 10.1111/j.1749-6632.2012.06674.x. Epub 2012 Jul 25. Review.

PMID:
22831177
21.

Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R.

Nat Rev Drug Discov. 2012 May;11(5):401-19. doi: 10.1038/nrd3705. Review.

PMID:
22543469
22.

Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

Dempster DW, Lambing CL, Kostenuik PJ, Grauer A.

Clin Ther. 2012 Mar;34(3):521-36. doi: 10.1016/j.clinthera.2012.02.002. Review.

PMID:
22440513
23.

Local delivery of recombinant osteoprotegerin enhances postorthodontic tooth stability.

Hudson JB, Hatch N, Hayami T, Shin JM, Stolina M, Kostenuik PJ, Kapila S.

Calcif Tissue Int. 2012 Apr;90(4):330-42. doi: 10.1007/s00223-012-9579-4. Epub 2012 Mar 1.

PMID:
22382900
24.

Transient muscle paralysis degrades bone via rapid osteoclastogenesis.

Aliprantis AO, Stolina M, Kostenuik PJ, Poliachik SL, Warner SE, Bain SD, Gross TS.

FASEB J. 2012 Mar;26(3):1110-8. doi: 10.1096/fj.11-196642. Epub 2011 Nov 28.

25.

Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation.

Zheleznyak A, Wadas TJ, Sherman CD, Wilson JM, Kostenuik PJ, Weilbaecher KN, Anderson CJ.

Mol Imaging Biol. 2012 Aug;14(4):500-8. doi: 10.1007/s11307-011-0512-4.

26.

Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury.

Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, Han CY, Yu L, Lee J, Lee E, Barrero M, Kurimoto P, Niu QT, Geng Z, Winters A, Horan T, Steavenson S, Jacobsen F, Chen Q, Haldankar R, Lavallee J, Tipton B, Daris M, Sheng J, Lu HS, Daris K, Deshpande R, Valente EG, Salimi-Moosavi H, Kostenuik PJ, Li J, Liu M, Li C, Lacey DL, Simonet WS, Ke HZ, Babij P, Stolina M, Ominsky MS, Richards WG.

J Bone Miner Res. 2011 Nov;26(11):2610-21. doi: 10.1002/jbmr.472.

27.

Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.

Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.

Endocrinology. 2011 Sep;152(9):3312-22. doi: 10.1210/en.2011-0252. Epub 2011 Jul 5.

PMID:
21733832
28.

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.

Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ.

Bone. 2011 Aug;49(2):162-73. doi: 10.1016/j.bone.2011.04.001. Epub 2011 Apr 9.

PMID:
21497676
29.

Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.

Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS.

Bone. 2011 Aug;49(2):151-61. doi: 10.1016/j.bone.2011.03.769. Epub 2011 Mar 30.

PMID:
21457806
30.

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.

Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.

J Bone Miner Res. 2010 Dec;25(12):2647-56. doi: 10.1002/jbmr.182. Epub 2010 Jul 16. Erratum in: J Bone Miner Res. 2011 Feb;26(2):439.

31.

Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.

Pierroz DD, Bonnet N, Baldock PA, Ominsky MS, Stolina M, Kostenuik PJ, Ferrari SL.

J Biol Chem. 2010 Sep 3;285(36):28164-73. doi: 10.1074/jbc.M110.101964. Epub 2010 Jun 17.

32.

Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice.

Helas S, Goettsch C, Schoppet M, Zeitz U, Hempel U, Morawietz H, Kostenuik PJ, Erben RG, Hofbauer LC.

Am J Pathol. 2009 Aug;175(2):473-8. doi: 10.2353/ajpath.2009.080957. Epub 2009 Jul 9. Erratum in: Am J Pathol. 2009 Nov;175(5):2249.

33.

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.

Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ.

Bone. 2009 Oct;45(4):669-76. doi: 10.1016/j.bone.2009.06.011. Epub 2009 Jun 17.

PMID:
19539794
34.

Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL.

Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schüler C, Stolina M, Kostenuik PJ, Erben RG.

Arthritis Rheum. 2009 May;60(5):1427-37. doi: 10.1002/art.24445.

35.

One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength.

Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ.

J Bone Miner Res. 2009 Jul;24(7):1234-46. doi: 10.1359/jbmr.090215.

36.

The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis.

Stolina M, Bolon B, Dwyer D, Middleton S, Duryea D, Kostenuik PJ, Feige U, Zack DJ.

Biomarkers. 2008 Nov;13(7):692-712. doi: 10.1080/13547500802651911 .

PMID:
19096963
37.

Effects of spaceflight on murine skeletal muscle gene expression.

Allen DL, Bandstra ER, Harrison BC, Thorng S, Stodieck LS, Kostenuik PJ, Morony S, Lacey DL, Hammond TG, Leinwand LL, Argraves WS, Bateman TA, Barth JL.

J Appl Physiol (1985). 2009 Feb;106(2):582-95. doi: 10.1152/japplphysiol.90780.2008. Epub 2008 Dec 12. Erratum in: J Appl Physiol. 2011 Jan;110(1):298.

38.

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C.

J Bone Miner Res. 2009 Apr;24(4):578-88. doi: 10.1359/jbmr.081206.

39.

Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.

Gerstenfeld LC, Sacks DJ, Pelis M, Mason ZD, Graves DT, Barrero M, Ominsky MS, Kostenuik PJ, Morgan EF, Einhorn TA.

J Bone Miner Res. 2009 Feb;24(2):196-208. doi: 10.1359/jbmr.081113.

40.

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK.

J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112.

41.

Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice.

Lloyd SA, Yuan YY, Kostenuik PJ, Ominsky MS, Lau AG, Morony S, Stolina M, Asuncion FJ, Bateman TA.

Calcif Tissue Int. 2008 May;82(5):361-72. doi: 10.1007/s00223-008-9133-6. Epub 2008 May 9.

PMID:
18465074
42.

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.

Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ.

J Bone Miner Res. 2008 May;23(5):672-82. doi: 10.1359/jbmr.080109.

43.

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C.

J Bone Miner Res. 2008 Jun;23(6):860-9. doi: 10.1359/jbmr.080216.

44.

Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL.

Circulation. 2008 Jan 22;117(3):411-20. doi: 10.1161/CIRCULATIONAHA.107.707380. Epub 2008 Jan 2.

45.

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.

Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC.

Clin Exp Metastasis. 2008;25(2):119-29. Epub 2007 Dec 5.

PMID:
18064531
46.

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Kearns AE, Khosla S, Kostenuik PJ.

Endocr Rev. 2008 Apr;29(2):155-92. Epub 2007 Dec 5. Review.

47.

Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease.

Yuan YY, Kostenuik PJ, Ominsky MS, Morony S, Adamu S, Simionescu DT, Basalyga DM, Asuncion FJ, Bateman TA.

Osteoporos Int. 2008 May;19(5):625-35. Epub 2007 Nov 24.

PMID:
18038244
48.

RANKL inhibition: from mice to men (and women).

Stolina M, Kostenuik PJ, Dougall WC, Fitzpatrick LA, Zack DJ.

Adv Exp Med Biol. 2007;602:143-50. Review.

PMID:
17966399
49.

RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.

Jin Q, Cirelli JA, Park CH, Sugai JV, Taba M Jr, Kostenuik PJ, Giannobile WV.

J Periodontol. 2007 Jul;78(7):1300-8.

50.

Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movement.

Dunn MD, Park CH, Kostenuik PJ, Kapila S, Giannobile WV.

Bone. 2007 Sep;41(3):446-55. Epub 2007 May 8.

Supplemental Content

Loading ...
Support Center